Nanoencapsulated ANP-801

ANP's Nanoencapsulation platform technology has shown promising pre-clinical results for our next generation immune-oncology (I/O) drug, NanoANP-801, a novel immune system modulator - poised to capture a large share of the non-responsive PD-1/PD-L1 immune checkpoint blocker (ICB) market valued at more than $24B.

 About Us           Collaborations          Careers           Contact Us

ANP Technologies®, Inc.

824 Interchange Boulevard  Newark, Delaware 19711

302-283-1730 | 302-283-1731 (Alternate Tel)

302-283-1733 (Fax)

  • Black Facebook Icon
  • Black Twitter Icon
  • Black YouTube Icon

Copyright 2020

ANP Technologies®, Inc.